About Synaffix
Synaffix is a Healthcare company based in Nijmegen (Netherlands) founded in 2010, and was acquired by Lonza in June 2023. Antibody-drug conjugate technology platform is developed for cancer therapies. It operates on a Licensing Model model. Synaffix offers products and services including GlycoConnect®, HydraSpace®, and toxSYN® Linker-Payloads. Its focus areas include Biotechnology and Antibody-Drug Conjugates. Its legal entity is Synaffix B.V.
Company details
Synaffix is engaged in the development of clinical-stage platform technologies for antibody-drug conjugates (ADCs) and bispecifics, primarily targeting cancer therapeutics. The companys proprietary solutions, including GlycoConnect, HydraSpace, and toxSYN linker-payloads, are designed to enable best-in-class targeted therapies. Operating under a technology out-licensing model, Synaffix collaborates with multiple partners to advance therapeutic candidates across preclinical and clinical phases. The focus is centered on the healthcare sector, specifically biotechnology, with an emphasis on innovative cancer treatment solutions.
- Headquarters Nijmegen, Netherlands
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website synaffix.com
- Social LinkedIn X
- Acquired by Lonza (Jun 2023)
- Legal Name Synaffix B.V.
Products & Services of Synaffix
Synaffix offers a comprehensive portfolio of products and services, including GlycoConnect®, HydraSpace®, and toxSYN® Linker-Payloads.
Technology for antibody-drug conjugate development is provided.
Spacer technology for enhanced ADC efficacy is offered.
Linker-payloads for targeted cancer therapies are developed.
Funding Insights of Synaffix
- Total Rounds 1
- Investors Count 4
All 1 funding rounds of Synaffix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2014 | Series A | – | – |
5 investors in total: 5 institutional.
Investors in Synaffix
Synaffix has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Lonza, BOM and BioGeneration Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life science focused VC firm investing in startups in Europe | biogenerationventures.com | Naarden, Netherlands | ||
Investments are directed by BOM toward early and growth-stage firms. | 1983 | bom.nl | Tilburg, Netherlands | |
Venture capital firm investing in multiple sectors | m-ventures.com | Amsterdam, Netherlands | ||
Growth capital is provided by Aravis for Swiss high-tech companies. | aravis.ch | Switzerland | ||
CDMO services for pharma, biotech, and specialty ingredients are provided. | 1897 | lonza.com | Basel, Switzerland |
Investor details for Synaffix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Synaffix
12 people are tracked at Synaffix (7 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Sander Van Berkel | Head Of External Collaborations | Leadership |
Anthony Deboer | Head Of Business Development | Leadership |
Peter van de Sande | CEO | Leadership |
Diana Čekatauskaitė | Associate Director, Business Development | Leadership |
Harold Jansen | Head Of Finance | Leadership |
Sven Zimmer | Associate Director Business Development & Licensing | Leadership |
Peter Tjeerdsma | VP CMC And Regulatory | Leadership |
Sanne van Zanten-Reulen | Project Lead External Collaborations | Team |
Marloes Wijdeven | Projectmanager R&d External Collaborations | Team |
Yi Ting P. | Alliance Management Lead Synaffix | Team |
Jord van Schaik | Process Engineer CMC Development | Team |
Albert Godoy Hernández | Project Manager CMC | Team |
Complete people profiles for Synaffix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Synaffix
3 dated milestones of Synaffix across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Synaffix is founded.
- Funding First funding round.
- Exit Acquired by Lonza.
Web traffic of Synaffix
The website of Synaffix (synaffix.com) receives about 3.5K visits a month.
- Monthly visits3.5K
▼ 41.3% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Synaffix
Complete news archive for Synaffix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synaffix
Synaffix was founded in 2010 and raised its 1st funding round 4 years after it was founded.
Synaffix is headquartered in Nijmegen, Netherlands. It is registered at Nijmegen, Gelderland, Netherlands.
Synaffix is engaged in the development of clinical-stage platform technologies for antibody-drug conjugates (ADCs) and bispecifics, primarily targeting cancer therapeutics. The companys proprietary solutions, including GlycoConnect, HydraSpace, and toxSYN linker-payloads, are designed to enable best-in-class targeted therapies. Operating under a technology out-licensing model, Synaffix collaborates with multiple partners to advance therapeutic candidates across preclinical and clinical phases. The focus is centered on the healthcare sector, specifically biotechnology, with an emphasis on innovative cancer treatment solutions.
Synaffix offers GlycoConnect®, HydraSpace®, and toxSYN® Linker-Payloads.
Synaffix has 5 investors. Key investors include Lonza, BOM, BioGeneration Ventures, M-Ventures, and Aravis.
Synaffix operates through Synaffix B.V..
Yes. Synaffix was acquired by Lonza in June 2023.